PositiveID Board Approves 1-for-25 Reverse Stock Split | GenomeWeb

NEW YORK (GenomeWeb News) – PositiveID said today its board has approved a 1-for-25 reverse stock split, commencing at the start of trading on April 23.

As a result of the reverse split, the number of PositiveID shares will be reduced to about 15 million shares. The company's ticker symbol will be PSIDD for about 20 trading days after the split to designate it is trading on a post-reverse split basis.

The company trades on the Over-The-Counter Bulletin Board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.